Literature DB >> 22656863

The large scale conformational change of the human DPP III-substrate prefers the "closed" form.

Antonija Tomić1, Miguel González, Sanja Tomić.   

Abstract

Human dipeptidyl peptidase III (DPP III) is a two domain metallo-peptidase from the M49 family. The wide interdomain cleft and broad substrate specificity suggest that this enzyme could experience significant conformational change. Long (>100 ns) molecular dynamics (MD) simulations of DPP III revealed large range conformational changes of the protein, suggesting the pre-existing equilibrium model for a substrate binding. The binding free energy calculations revealed tighter binding of the preferred synthetic substrate Arg-Arg-2-naphtylamide to the "closed" than to the "open" DPP III conformation. Our assumption that Asp372 plays a crucial role in the large scale interdomain closure was proved by the MD simulations of the Asp372Ala variant. During the same simulation time, the variant remained more "open" than the wild type protein. Apparently, Ala was not as efficient as Asp in establishing the interdomain interactions. According to the MM-PBSA calculations, the electrostatic component of the free energy of solvation turned out to be higher for the "closed" protein than for its less compact form. However, the gain in entropy due to water released from the interdomain cleft nicely balanced this negative effect.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22656863     DOI: 10.1021/ci300141k

Source DB:  PubMed          Journal:  J Chem Inf Model        ISSN: 1549-9596            Impact factor:   4.956


  6 in total

1.  Conservation of the conformational dynamics and ligand binding within M49 enzyme family.

Authors:  Saša Kazazić; Zrinka Karačić; Igor Sabljić; Dejan Agić; Marko Tomin; Marija Abramić; Michal Dadlez; Antonija Tomić; Sanja Tomić
Journal:  RSC Adv       Date:  2018-04-10       Impact factor: 4.036

Review 2.  Survey of Dipeptidyl Peptidase III Inhibitors: From Small Molecules of Microbial or Synthetic Origin to Aprotinin.

Authors:  Marija Abramić; Dejan Agić
Journal:  Molecules       Date:  2022-05-07       Impact factor: 4.927

3.  Coumarin Derivatives Act as Novel Inhibitors of Human Dipeptidyl Peptidase III: Combined In Vitro and In Silico Study.

Authors:  Dejan Agić; Maja Karnaš; Domagoj Šubarić; Melita Lončarić; Sanja Tomić; Zrinka Karačić; Drago Bešlo; Vesna Rastija; Maja Molnar; Boris M Popović; Miroslav Lisjak
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-05

4.  The first dipeptidyl peptidase III from a thermophile: Structural basis for thermal stability and reduced activity.

Authors:  Igor Sabljić; Marko Tomin; Mihaela Matovina; Iva Sučec; Ana Tomašić Paić; Antonija Tomić; Marija Abramić; Sanja Tomić
Journal:  PLoS One       Date:  2018-02-08       Impact factor: 3.240

5.  Demystifying DPP III Catalyzed Peptide Hydrolysis-Computational Study of the Complete Catalytic Cycle of Human DPP III Catalyzed Tynorphin Hydrolysis.

Authors:  Antonija Tomić; Sanja Tomić
Journal:  Int J Mol Sci       Date:  2022-02-06       Impact factor: 5.923

6.  A novel Porphyromonas gingivalis enzyme: An atypical dipeptidyl peptidase III with an ARM repeat domain.

Authors:  Altijana Hromić-Jahjefendić; Nina Jajčanin Jozić; Saša Kazazić; Marina Grabar Branilović; Zrinka Karačić; Jörg H Schrittwieser; Krishna Mohan Padmanabha Das; Marko Tomin; Monika Oberer; Karl Gruber; Marija Abramić; Sanja Tomić
Journal:  PLoS One       Date:  2017-11-30       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.